3.17
+0.34(+12.01%)
Currency In USD
| Previous Close | 2.83 |
| Open | 2.91 |
| Day High | 3.49 |
| Day Low | 2.89 |
| 52-Week High | 9.2 |
| 52-Week Low | 2.57 |
| Volume | 412,687 |
| Average Volume | 47,867 |
| Market Cap | 27.36M |
| PE | -0.56 |
| EPS | -5.67 |
| Moving Average 50 Days | 3.84 |
| Moving Average 200 Days | 4.75 |
| Change | 0.34 |
If you invested $1000 in Clene Inc. (CLNN) since IPO date, it would be worth $16.26 as of April 25, 2025 at a share price of $3.17. Whereas If you bought $1000 worth of Clene Inc. (CLNN) shares 5 years ago, it would be worth $14.95 as of April 25, 2025 at a share price of $3.17.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Clene to Present at the Emerging Growth Conference
GlobeNewswire Inc.
Apr 14, 2025 12:30 PM GMT
SALT LAKE CITY, April 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to advancing therapies
Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session
GlobeNewswire Inc.
Apr 08, 2025 12:00 PM GMT
Analyses of MRI and VEP data confirm anatomical and physiological improvements, indicating remyelination and neuronal repair in the brains of MS patients treated with CNM-Au8 during the long-term extension of VISIONARY-MSOver 90% of participants who
Clene to Present at the Jones Healthcare and Technology Innovation Conference
GlobeNewswire Inc.
Apr 01, 2025 12:30 PM GMT
SALT LAKE CITY, April 01, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing